High-dose intravenous insulin infusion versus intensive insulin treatment in newly diagnosed IDDM

Diabetes

Volumn 46, Issue 10, 1997, Pages 1612-1618

  Allen, Terri J ^a,c   Cao, Zemin ^a   Youssef, Sherif ^a   Hulthen, U Lennart ^b   Cooper, Mark E ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c AUSTIN HEALTH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; INSULIN; ANGIOTENSIN II; BRADYKININ; BRADYKININ RECEPTOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DRUG DERIVATIVE; ICATIBANT; RAMIPRIL; TETRAZOLE DERIVATIVE; VALINE; VALSARTAN;

ADULT; ARTICLE; CLINICAL ARTICLE; DIAGNOSTIC ACCURACY; DISEASE CONTROL; DOSE RESPONSE; DRUG MEGADOSE; FEMALE; FOLLOW UP; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; INTRAVENOUS DRUG ADMINISTRATION; MALE; PRIORITY JOURNAL; TREATMENT PLANNING; ALBUMINURIA; ANIMAL; BLOOD PRESSURE; CHEMISTRY; DIABETIC NEPHROPATHY; DRUG ANTAGONISM; EXPERIMENTAL DIABETES MELLITUS; GLOMERULUS; KIDNEY; ORGAN SIZE; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; RAT; SPRAGUE DAWLEY RAT; ULTRASTRUCTURE;

ALBUMINURIA; ANGIOTENSIN II; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; BLOOD PRESSURE; BRADYKININ; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; KIDNEY; KIDNEY GLOMERULUS; MALE; ORGAN SIZE; RAMIPRIL; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, BRADYKININ; TETRAZOLES; VALINE;

EID: 0031252397     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.46.10.1612     Document Type: Article

References (66)

1. Blantz RC, Konnen KS, Tucker BJ: Angiotensin II effects upon the glomerular microcirculation and ultrafiltration coefficient of the rat. J Clin Invest 57:419-434, 1976
2. Geisterfer AAT, Peach MJ, Owens GK: Angiotensin II induces hypertrophy, not hyperplasia, of cultured rat aortic smooth muscle cells. Circ Res 62:749-756, 1988
3. Zatz R, Meyer TW, Rennke HG, Brenner BM: Predominance of hemodynamic rather than metabolic factors in the pathogenesis of diabetic glomerulopathy. Proc Natl Acad Sci USA 82:5963-5967, 1985
4. Allen TJ, Cooper ME, O'Brien RC, Bach LA, Jackson B, Jerums G: Glomerular filtration rate in the streptozocin diabetic rat: the role of exchangeable sodium, vasoactive hormones and insulin therapy. Diabetes 38:1182-1190, 1990
5. Kennefick TM, Oyama TT, Thompson MM, Vora JP, Anderson S: Enhanced renal sensitivity to angiotensin actions in diabetes mellitus in the rat. Am J Physiol 271:F595-F602, 1996
6. Zatz R, Dunn BR, Meyer TW, Brenner B: Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J Clin Invest 77:1925-1930, 1986
7. Cooper ME, Rumble JR, Allen T, O'Brien RC, Jerums G, Doyle AE: Antihypertensive therapy in a model combining spontaneous hypertension with diabetes. Kidney Int 41:898-903, 1992
8. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD: The effect of angiotensin converting enzyme inhibition on diabetic nephropathy. N Engl J Med 329:1456-1462, 1993
9. Erdos EG: Conversion of angiotensin I to angiotensin II. Ann Rev Med 60:749-759, 1976
10. Ignarro LI, Bug GM, Chaudhuri G: EDRF generation and release from perfused bovine pulmonary artery and vein. Eur J Pharmacol 149:79-88, 1990
11. Komers R, Cooper ME: Acute renal haemodynamic effects of angiotensin converting enzyme inhibition in diabetic hyperfiltration: the role of kinins. Am J Physiol 268:F588-F594, 1995
12. Mayfield RK, Margolius HS, Bailey GS, Miller DH, Sens DA, Squires J, Namm DH: Urinary and renal tissue kallikrein in the streptozocin-diabetic rat. Diabetes 34:22-28, 1985
13. Johnston CI: Angiotensin receptor antagonists: focus on losartan. Lancet 346:1403-1407, 1995
14. Rhaleb NE, Rouissi N, Jukic D, Regoli D, Henke S, Breipohl G, Knolle J: Pharmacological characterization of a new highly potent B2 receptor antagonist (HOE 140: D-Arg-[Hyp3,Thi5,D-Tic7,Qic8]bradykinin). Eur J Pharmacol 210:115-120, 1992
15. Remuzzi A, Perico N, Amuchastegui CS, Malanchini B, Mazerska M, Battaglia C, Bertani T, Remuzzi G: Short- and long-term effect of angiotensin II receptor blockade in rats with experimental diabetes. J Am Soc Nephrol 4:40-49, 1993
16. Bunag RD: Validation in awake rats of a tail-cuff method for measuring systolic pressure. J Appl Physiol 34:279-282, 1973
17. Soulis-Liparota T, Cooper ME, Dunlop M, Jerums G: The relative roles of advanced glycation, oxidation and aldose reductase inhibition in the development of experimental diabetic nephropathy in the Sprague-Dawley rat. Diabetologia 38:387-394, 1995
18. Mendelsohn FAO, Hutchinson J, Johnston CI: A review of plasma renin measurements and their clinical significance. Aust NZ J Med 1:86-93, 1971
19. Alla SA, Buschko J, Quitterer U, Maidhof A, Haasemann M, Breipohl G, Knolle J, Muller Esterl W: Structural features of the human bradykinin B2 receptor probed by agonists, antagonists, and anti-idiotypic antibodies. J Biol Chem 268:17277-17285, 1993
20. Cooper ME, Allen TJ, O'Brien R, Clarke B, Jerums G, Doyle AE: Effects of genetic hypertension on diabetic nephropathy in the rat functional and structural characteristics. J Hypertension 6:1009-1016, 1988
21. Andrews PM, Coffey AK: A technique to reduce fixation artifacts to kidney proximal tubules. Kidney Int 25:964-968, 1984
22. Jensen EB, Gundersen HJG, Osterby R: Determination of membrane thickness distribution from orthogonal intercepts. J Microsc 115:19-33, 1979
23. Weibel ER: Stereological Methods: Practical Methods for Biological Morphometry. Vol. 1. London, Academic Press, 1979
24. Mauer SM, Steffes MW, Ellis EN, Sutherland DER, Brown DM, Goetz FC: Structural-functional relationship in diabetic nephropathy. J Clin Invest 74:1143-1155, 1984
25. Snedecor GW, Cochran WG: One-way classifications: analysis of variance. In Statistical Methods. 7th ed. Ames, Iowa, Iowa State University Press, 1980, p. 215-236
26. Christlieb AR, Boston MD: Renin, angiotensin and norepinephrine in alloxan diabetes. Diabetes 23:962-970, 1974
27. Anderson S, Jung FF, Ingelfinger JR: Renal renin-angiotensin system in diabetes: functional, immunohistochemical, and molecular biological correlations. Am J Physiol 265:F477-F486, 1993
28. Yoshida Y, Fogo A, Ichikawa I: Glomerular hemodynamic changes vs. hypertrophy in experimental glomerular sclerosis. Kidney Int 36:654-660, 1989
29. Fogo A, Ichikawa I: Evidence for a pathogenic linkage between glomerular hypertrophy and sclerosis. Am J Kidney Dis 17:666-669, 1991
30. Anderson PW, Do YS, Hsueh WA: Angiotensin II causes mesangial cell hypertrophy. Hypertension 21:29-35, 1993
31. Vranes D, Dilley RJ, Cooper ME: Perindopril attenuates diabetes associated vascular hypertrophy. J Diabetes Complications 9:296-300, 1994
32. Allen TJ, Hulthen UL, Rumble J, Jasik M, Cooper ME: Diabetic vascular hypertrophy and albuminuria: role of ACE inhibition. J Diabetes Complications 9:318-322, 1995
33. Harvey JN: Renal excretion of kallikrein and eicosanoids in patients with type 1 (insulin-dependent) diabetes mellitus: relationship to glomerular and tubular function. Diabetologia 35:857-862, 1992
34. Jaffa AA, Chai KX, Chao J, Chao L, Mayfield RK: Effects of diabetes and insulin on expression of kallikrein and renin genes in the kidney. Kidney Int 41:789-795, 1992
35. Jaffa AA, Rust PF, Mayfield RK: Kinin, a mediator of diabetes-induced glomerular hyperfiltration. Diabetes 44:156-160, 1995
36. Vora JP, Oyama TT, Thompson MM, Anderson S: Interactions of reninangiotensin (RAS) and kallikrein-kinin (KKS) systems in the diabetic kidney. Diabetes 46:107-112, 1997
37. Kon V, Fogo A, Ichikawa I: Bradykinin causes selective efferent arteriolar dilatation during angiotensin I converting enzyme inhibition. Kidney Int 44:545-550, 1993
38. Rumble J, Komers R, Cooper M: Kinins/nitric oxide are involved in the anti-trophic effects of ACE inhibitors on diabetes associated mesenteric vascular hypertrophy. J Hypertension 14:601-607, 1996
39. Hutchison FN, Cui X, Webster SK: The antiproteinuric action of angiotensin-converting enzyme is dependent on kinin. J Am Soc Nephrol 6:1216-1222, 1995
40. Figueroa CD, Gonzalez CB, Grigoriev S, Abd Alla SA, Haasemann M, Jarnagin K, Muller Esterl W: Probing for the bradykinin B2 receptor in rat kidney by anti-peptide and anti-ligand antibodies. J Histochem Cytochem 43:137-148, 1995
41. Linz W, Scholkens BA: A specific B2-bradykinin receptor antagonist Hoe 140 abolishes antihypertrophic effect of ramipril. Br J Pharmacol 105:771-772, 1992
42. Farhy RD, Carretero OA, Ho K-L, Scicli AG: Role of kinins and nitric oxide in the effects of angiotensin converting enzyme inhibitors on neointima formation. Circ Res 72:1202-1210, 1993
43. MacDougall M, Cowley B, Wiegmann T: Bradykinin mediates effects of ramipril on diabetic glomerular hypertrophy and albuminuria independent of blood pressure effect (Abstract). J Am Soc Nephrol 6:1044, 1996
44. Tanaka R, Kon V, Yoshioka T, Ichikawa I, Fogo A: Angiotensin converting enzyme inhibitor modulates glomerular function and structure by distinct mechanisms. Kidney Int 45:537-543, 1994
45. Criscione L, de Gasparo M, Buhlmayer P, Whitebread S, Ramjoue HP, Wood J: Pharmacological profile of valsartan: a potent orally active, nonpeptide antagonist of the angiotensin II AT-1 receptor subtype. Br J Pharmacol 110:761-771, 1993
46. Kasiske BL, O'Donnell MP, Keane WF: The obese Zucker rat model of glomerular injury in type II diabetes. J Diabetic Complications 1:26-29, 1987
47. Harker CT, O'Donnell MP, Kasiske BL, Keane WF, Katz SA: The renin-angiotensin system in the type II diabetic obese Zucker rat. J Am Soc Nephrol 4:1354-1361, 1993
48. Crary GS, Swan SK, O'Donnell MP, Kasiske BL, Katz SA, Keane WF: The angiotensin II receptor antagonist losartan reduces blood pressure but not renal injury in obese Zucker rats. J Am Soc Nephrol 6:1295-1299, 1995
49. Lafayette RA, Mayer G, Park SK, Meyer TW: Angiotensin II receptor blockade limits glomerular injury in rats with reduced renal mass. J Clin Invest 90:766-771, 1992
50. Kakinuma Y, Kawamura T, Bills T, Yoshioka T, Ichikawa I, Fogo A: Blood pressure-independent effect of angiotensin inhibition on vascular lesions of chronic renal failure. Kidney Int 42:46-55, 1992
51. Wu L, Roe C, Cox A, Dziadek M, Cooper ME, Gilbert RE: Transforming growth factor β1 and renal injury following subtotal nephrectomy in the rat: Role of the renin-angiotensin system. Kidney Int 51:1553-1567, 1997
52. Mentzel S, Assman KJM, Dijkman HBPM, de Jong AS, van Son JPHF, Wetzels JFM, Koene RAP: Inhibition of aminopeptidase A activity causes an acute albuminuria in mice: an angiotensinII-mediated effect? Nephrol Dial Transplant 11:2163-2169, 1996
53. Remuzzi A, Fassi A, Sangali F, Malanchin B, Remuzzi B: Effect of benazapril and valsartan on glomerular injury in experimental diabetes in MWF/Ztm rats (Abstract). J Am Soc Nephrol 7:1877, 1996
54. Kohzuki M, Yasujima M, Kanazawa M, Yoshida K, Fu LP, Obara K, Saito T, Abe K: Antihypertensive and renal-protective effects of losartan in streptozotocin diabetic rats. J Hypertens 13:97-103, 1995
55. Cooper ME, Allen TJ, O'Brien RC, Papazoglou D, Clarke BE, Jerums G, Doyle AE: Nephropathy in model combining genetic hypertension with experimental diabetes: enalapril versus hydralazine and metoprolol therapy. Diabetes 39:1575-1579, 1990
56. Rasch R: Prevention of diabetic glomerulopathy in streptozotocin diabetic rats by insulin treatment: the mesangial regions. Diabetologia 17:243-248, 1979
57. Steffes MW, Brown DM, Basgen JM, Mauer SM: Amelioration of mesangial volume and surface alterations following islet transplantation in diabetic rats. Diabetes 29:509-515, 1980
58. Petersen J, Ross J, Rabkin R: Effect of insulin therapy on established diabetic nephropathy in rats. Diabetes 37:1346-1350, 1988
59. Soulis-Liparota T, Cooper M, Papazoglou D, Clarke B, Jerums G: Retardation by aminoguanidine of development of albuminuria, mesangial expansion, and tissue fluorescence in streptozocin-induced diabetic rat. Diabetes 40:1328-1334, 1991
60. Sassy Prigent C, Heudes D, Jouquey S, Auberval D, Belair MF, Michel O, Hamon G, Bariety J, Bruneval P: Morphometric detection of incipient glomerular lesions in diabetic nephropathy in rats: protective effects of ACE inhibition. Lab Invest 73:64-71, 1995
61. Dzau V: Circulating versus local renin-angiotensin system in cardiovascular homeostasis. Circulation 77 (Suppl. 1):1-4, 1988
62. Johnston CI, Burrell LM, Perich R, Jandeleit K, Jackson B: The tissue renin-angiotensin system and its functional role. Clin Exp Pharmacol Physiol Suppl 19:1-5, 1992
63. Cooper ME, Allen TJ, Macmillan PA, Clarke BA, Jerums G, Doyle AE: Enalapril retards albuminuria and glomerular basement membrane thickening in experimental diabetic nephropathy. Diabetologia 32:326-328, 1989
64. Border WA, Yamamoto T, Noble NA: Transforming growth factor β in diabetic nephropathy. Diabetes Metab Rev 12:309-339, 1996
65. Hutchison FN, Cui X, Paul RV, Oliverio M, Coffman TM: Increase in renal transforming growth factor β in diabetes is angiotensin II dependent (Abstract). J Am Soc Nephrol 7:1872, 1995
66. Yamamoto T, Nakamura T, Noble NA, Ruoslahti E, Border WA: Expression of transforming growth factor beta is elevated in human and experimental diabetic nephropathy. Proc Natl Acad Sci USA 90:1814-1818, 1993